BRTX

Over the past six months, several events have impacted BRTX's stock price. In November 2025, the company reported its Q3 financial results, noting a revenue decrease and an increased net loss, while strengthening its financial position through a registered direct offering and a private placement. In February 2026, BioRestorative Therapies completed the enrollment of 99 patients in its Phase 2 trial for BRTX-100 and reported a positive outcome from a Type B meeting with the FDA regarding BRTX-100. In March 2026, the company issued a letter to shareholders, highlighting significant milestones, and reported expanded Phase 2 blinded data for BRTX-100. In April 2026, BioRestorative Therapies announced a strategic collaboration with 203 Creates and a strategic partnership with Dr. David J. Goldberg for the BioCosmeceutical platform and presented new data at ISCT 2026. In May 2026, the company reported expanded Phase 2 blinded dataset for BRTX-100. Despite these advancements, the company's share price experienced a significant decline.